Nasdaq (Nasdaq:NDAQ) today announced OPK added to NBI.

NEW YORK, Dec. 12, 2016 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 19, 2016.

The following 21 securities will be added to the Index:

Exchange SYMBOL COMPANY NAME
Nasdaq AIMT Aimmune Therapeutics, Inc.
Nasdaq ARLZ Aralez Pharmaceuticals Inc.
Nasdaq AVXS AveXis, Inc.
Nasdaq BGNE BeiGene, Ltd.
Nasdaq BOLD Audentes Therapeutics
Nasdaq CLCD CoLucid Pharmaceuticals
Nasdaq CLSD Clearside Biomedical, Inc.
Nasdaq CYTK Cytokinetics, Incorporated
Nasdaq EDIT Editas Medicine, Inc.
Nasdaq GBT Global Blood Therapeutics
Nasdaq ITCI Intra-Cellular Therapies
Nasdaq LOXO Loxo Oncology, Inc.
Nasdaq MNOV Medicinova Inc
Nasdaq NERV Minerva Neurosciences
Nasdaq NH NantHealth, Inc.
Nasdaq NTLA Intellia Therapeutics, Inc.
Nasdaq NVCR NovoCure Limited
Nasdaq ONVO Organovo Holdings Inc
Nasdaq OPK OPKO Health, Inc.
Nasdaq PRTK Paratek Pharmaceuticals, Inc.
Nasdaq RGNX REGENXBIO Inc.